the adc therapeutics ( gdc ) program is a novel and promising drug for the treatment of patients with b-cell non - hodgkin lymphoma. this is a report of our second quarter of the launch and its impact on our clinical and regulatory development goals. we are now approximately six months into the launch and we are encouraged by what we have accomplished to date delivering $13.1 million in net sales in our first quarter of the launch. we have generated good momentum behind the launch driven by the unique product profile with the significant unmet medical need in third line-plus bilateral lymphoma and the strong execution of our highly experienced team of sales and medical professionals. we continue to advance our pipeline programs and are actively progressing our pipelines. we continue to advance our pipelines and we are well positioned to execute on all aspects of the business.